Moldova’s Oncology Procurement 2026: A $6.1 Million Invitation and Untapped Opportunities for Global Pharma

Introduction

The Moldova oncology procurement for 2026 has confirmed a significant commitment to investing in high-cost, innovative cancer therapies. Based on the recently concluded public procurement results for oncology and immunosuppressive medicines for 2026, the country’s demand presents a substantial, two-pronged opportunity for foreign manufacturers, marketing authorization holders (MAHs), and exporters: securing high-value contracts and filling critical supply gaps.

The procurement process has delivered contracts worth over $6.1 Million USD (VAT-exclusive), signaling a strategic focus on securing advanced treatments. This data provides a clear roadmap for international suppliers looking to establish or expand their presence in this dynamic Eastern European market.

Strategic Demand in the Moldova Oncology Procurement: High-Value Therapies

The list of awarded contracts is dominated by innovative, targeted oral and injectable therapies, underscoring Moldova’s push to align its treatment protocols with current global oncology standards.

The highest-value contracts were secured for sophisticated molecules used in the treatment of solid tumors and hematological malignancies. The top five compounds alone account for approximately $3.83 Million USD, or over 62% of the total value of attributed contracts for 2026:

INN

Dose

Pharmaceutical form

Contract value (USD, Excl. VAT)

Ibrutinibum

140 mg

capsule

1,123,544.28

Vemurafenibum

240 mg 

tablet

1,064,772.20

Pertuzumabum + Trastuzumabum

1200 mg + 600 mg

solution for subcutaneous injection

652,271.53

Pertuzumabum

420 mg

conc./sol. infusion

567,588.05

Erlotinibum

150 mg

tablet

419,027.39

Key Investment Segments

Beyond the top five, the Moldova oncology procurement data reveals consistent, high-volume demand across core therapeutic areas:

  • Biologics and Monoclonal Antibodies (MAbs): High spending is maintained on biosimilars and originator MAbs, crucial for treating breast and colorectal cancers:

    • Trastuzumabum (various doses): Total value over $487,000 USD.

    • Rituximabum (various doses): Total value over $367,000 USD.

  • Classical Chemotherapy and Support: Core agents like Capecitabinum (over $198,000 USD) and Platinum Compounds (combined contracts exceeding $241,000 USD) remain essential for foundational cancer care.

Key International Manufacturers Dominating Moldova’s Oncology Market

The analysis of the Moldova oncology procurement results for 2026 highlights the key international pharmaceutical producers that successfully secured contracts. The market is primarily served by major Western European innovators for high-value targeted therapies and specialized Indian manufacturers for essential generic and biosimilar medicines.

The manufacturers that won the highest total contract value are:

  • Roche Group (Pertuzumabum, Pertuzumabum + Trastuzumabum, Vemurafenibum),
  • Janssen/J&J (Ibrutinibum, Doxorubicinum (pegylated liposomal)),
  • AryoGen Pharmed (Rituximabum, Bevacizumabum),
  • KRKA (Erlotinibum),
  • Naprod Life Sciences (Doxorubicinum, Epirubicinum, Paclitaxelum),
  • Accord Healthcare Group (Capecitabinum, Gemcitabinum, Topotecanum, Temozolomidum).

Untapped Opportunities

While Moldova successfully secured the majority of its needed medicines, the initial tender results also revealed critical gaps in supply for essential drugs, resulting in cancelled lots. Exemples include:

INN

Dose

Pharmaceutical form

Cause for cancel

Ibandronic Acid

6 mg/6 ml

conc./sol. infusion

Offered prices exceeded budget by >30%.

Etoposidum

100 mg/5 ml

conc./sol. infusion

Offered prices exceeded budget by >30%.

Immunoglobulinum humanum antihepaticum

2000-2500 UI 40-50 ml

solution for infusion

Offered prices exceeded budget by >30%.

Obinutuzumabum

1000 mg/40 ml

conc./sol. infusion

Offered prices exceeded budget by >30%.

Daratumumabum

1800 mg/15 ml

solution for injection

Offered prices exceeded budget by >30%.

The public buyer’s need for these molecules is confirmed and urgent. This is the optimal moment for international companies to intervene, fill the supply void, and gain a decisive foothold in the Moldovan public sector.

Call to Action: Secure Your End-to-End Market Position

The foundation for securing any part of the Moldova oncology procurement budget is official drug registration. Without it, you cannot bid.

Lismedfarm is your reliable, full-service partner specializing in Regulatory Affairs, Market Access, and Pharmaceutical Distribution in Moldova. For over 10 years, we have provided foreign manufacturers and MAHs with the complete infrastructure needed to succeed, from dossier submission to final patient delivery:

  1. Regulatory Affairs & MAH Representation: We act as your Marketing Authorization Holder (MAH) Representative, managing the entire drug registration process (in CTD/eCTD format) to ensure immediate eligibility for tenders.

  2. Market Access & Tender Strategy: Utilize our full procurement analysis to set a winning pricing strategy and ensure flawless bid preparation for both public tenders and urgent re-tenders.

  3. End-to-End Distribution & Logistics: Go beyond registration. We offer complete GDP compliant distribution solutions, including import, customs clearance, secure warehousing, Pharmacovigilance (PV), Quality Assurance (QA), and final delivery to all points of care across Moldova.

The time for comprehensive market entry is now. Partner with a single, trusted entity for full control from factory to patient.

Contact Lismedfarm today to launch your end-to-end operation in the Republic of Moldova or to get full detailed results of the Moldova oncology procurement for 2026.